文献速递乳腺癌放疗胸部肿瘤放疗

乳腺癌放疗后长达12年的肺功能与肺纤维化

Pulmonary Function and Lung Fibrosis up to 12 Years After Breast Cancer Radiotherapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-12-14

本研究纳入250例接受术后放疗的乳腺癌患者,随访至放疗后12年,评估肺功能、放射性纤维化(RF)与患者报告呼吸困难。结果显示化疗和局部区域放疗影响肺功能检查(PFT)表现至12年;放疗后3个月VC、FVC、FEV1下降预测长期PFT值下降,但长期PFT下降与长期RF或患者报告呼吸困难无关。

要点

  • 放疗后3个月VC、FEV1、FVC下降并长期维持低位,DLCO除外,其至12年时升高。
  • 化疗与局部区域放疗分别影响PFT变化;早期PFT下降预测长期PFT下降。
  • 长期随访91%患者见RF(主要为1级),重度呼吸困难少,与RF或PFT下降无显著关联。

核心结论

  • 化疗和局部区域放疗影响放疗后长达12年的PFT表现。
  • 放疗后3个月VC、FVC、FEV1下降预测长期随访PFT值下降(P=.020、P=.020、P=.004)。
  • 长期PFT值下降与长期RF或患者报告呼吸困难无显著关联。

研究设计与样本

  • 纳入250例转诊至术后放疗的乳腺癌患者。
  • 放疗前及放疗后3、6、12个月并至12年评估高分辨率CT、PFT、临床检查及患者报告呼吸困难。

主要发现

  • VC、FEV1、FVC和DLCO在放疗后3个月下降,除DLCO外长期随访维持低位;DLCO至放疗后12年升高。
  • VC、FEV1、FVC变化在化疗与未化疗患者间存在差异;FEV1在局部区域放疗与局部放疗患者间存在差异。
  • 放疗后3个月VC、FEV1、FVC下降预测长期PFT值下降(P=.020、P=.004、P=.020)。
  • 长期随访91%患者见RF,主要为1级。
  • 长期随访少数患者报告重度呼吸困难,与同期RF或PFT较基线下降无统计学显著关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer (BC) treatment may affect pulmonary function, but evidence of long-term pulmonary toxicity is scarce. This study aimed to evaluate pulmonary function, radiation fibrosis (RF), and patient-reported dyspnea up to 12 years after different BC treatment modalities. METHODS AND MATERIALS: Two hundred fifty patients with BC referred to postoperative radiotherapy (RT) were included in this study. High-resolution computed tomography, pulmonary function tests (PFTs), clinical examinations, and patient-reported dyspnea were assessed before RT and at 3, 6, and 12 months and up to 12 years after RT. RESULTS: Vital capacity (VC), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and diffusion capacity of the lungs for carbon monoxide (DLCO) declined at 3 months after RT and remained low at long-term follow-up except for DLCO, which increased up to 12 years after RT. VC, FEV1, and FVC changes differed between patients treated with and without chemotherapy, and FEV1 differed between patients treated with locoregional and local RT. An early decline in VC, FEV1, and FVC predicted a late decline in PFT values up to 12 years after RT (P = .020, P = .004, and P = .020, respectively). RF, mainly grade 1, was observed in 91% of patients at long-term follow-up. Few patients reported severe dyspnea at long-term follow-up, and there was no statistically significant association with concurrent RF or decline in PFT values from baseline. CONCLUSIONS: Chemotherapy and locoregional RT affected performance in PFTs up to 12 years after RT. Reduction in VC, FVC, and FEV1 3 months after RT predicted a decline in PFT values at long-term follow-up. However, a late decline in PFT values was not associated with long-term RF or patient-reported dyspnea.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Karlsen J, Tandstad T, Steinshamn S, et al. Pulmonary Function and Lung Fibrosis up to 12 Years After Breast Cancer Radiotherapy. Int J Radiat Oncol Biol Phys. 2023. PMID: 38099884. doi:10.1016/j.ijrobp.2023.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。